Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Visterra has dosed the first patient in the VIS410 Phase 2a clinical trial to study the monoclonal antibody for the treatment of hospitalized patients with influenza A, irrespective of the viral strain.
Subscribe to our email newsletter
This global Phase 2a clinical trial is being conducted in approximately 150 ambulatory patients diagnosed with influenza A. Patients in the Phase 2a clinical trial will be randomized into one of three arms to receive either 2000 mg of VIS410, 4000 mg of VIS410, or placebo.
The primary endpoint of the study is safety and tolerability and secondary endpoints include clinical symptoms of influenza, virology and pharmacokinetics of VIS410.
This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201500018C.
VIS410 is a monoclonal antibody designed and engineered to target all known strains of influenza A and is being developed to treat hospitalized patients with influenza A.
VIS410 is directed against a specific epitope, which we refer to as a Hierotope, on hemagglutinin, which is a surface protein of influenza viruses used for binding and entry into cells.
VIS410 is designed to prevent fusion of the influenza virus with host cell membranes by binding to hemagglutinin and thereby terminating the viral replication cycle.